Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Phase 4 Withdrawn Innovaderm Research Inc. Ciusss de L'Est de l'Île de Montréal · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study to evaluate the effects of bimekizumab in patients with psoriasis vulgaris and who also have active psoriatic arthritis (PsA).

Timeline

Start: 2023-01
Primary completion: 2023-09
Completion: 2024-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimekizumab	Monoclonal antibody	320 mg	Subcutaneous

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Summary

Timeline

Drugs

Indications